

Amina Jindani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5798762/publications.pdf>

Version: 2024-02-01

13
papers

1,107
citations

933447

10
h-index

1199594

12
g-index

14
all docs

14
docs citations

14
times ranked

1467
citing authors

#	ARTICLE	IF	CITATIONS
1	High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis. <i>New England Journal of Medicine</i> , 2014, 371, 1599-1608.	27.0	383
2	Bactericidal and Sterilizing Activities of Antituberculosis Drugs during the First 14 Days. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 167, 1348-1354.	5.6	287
3	Deaths from tuberculosis in sub-Saharan African countries with a high prevalence of HIV-1. <i>Lancet</i> , The, 2001, 357, 1519-1523.	13.7	151
4	Efficacy and Safety of a 4-Drug Fixed-Dose Combination Regimen Compared With Separate Drugs for Treatment of Pulmonary Tuberculosis. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1415.	7.4	88
5	Use of whole-genome sequencing to distinguish relapse from reinfection in a completed tuberculosis clinical trial. <i>BMC Medicine</i> , 2017, 15, 71.	5.5	57
6	Moxifloxacin Population Pharmacokinetics and Model-Based Comparison of Efficacy between Moxifloxacin and Ofloxacin in African Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 503-510.	3.2	38
7	Moxifloxacin Population Pharmacokinetics in Patients with Pulmonary Tuberculosis and the Effect of Intermittent High-Dose Rifapentine. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4471-4473.	3.2	30
8	Isoniazid Activity Is Terminated by Bacterial Persistence. <i>Journal of Infectious Diseases</i> , 2007, 195, 1871-1872.	4.0	23
9	Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 866-877.	5.6	22
10	A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	16
11	Challenges to the development of new drugs and regimens for tuberculosis. <i>Tuberculosis</i> , 2010, 90, 168-170.	1.9	7
12	Predictors of delayed culture conversion among Ugandan patients. <i>BMC Infectious Diseases</i> , 2017, 17, 299.	2.9	5
13	Denis Anthony Mitchison. <i>BMJ: British Medical Journal</i> , 0, , k3518.	2.3	0